{"product_id":"utmd-vrio-analysis","title":"Utah Medical Products, Inc. (UTMD): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Utah Medical Products, Inc. (UTMD) truly built for lasting success? This VRIO analysis cuts straight to the heart of their competitive advantage, scrutinizing if their key assets are Valuable, Rare, Inimitable, and Organized. Dive in now to see the distilled verdict on their sustainability and what it means for their future dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUtah Medical Products, Inc. (UTMD) - VRIO Analysis: 1. Debt-Free, Robust Balance Sheet\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at a balance sheet that lets Utah Medical Products, Inc. shrug off the sales pressure seen in 2025. The core takeaway is this: zero debt combined with significant liquidity provides a massive strategic cushion. This isn't just about having money; it's about the freedom that money buys when things get tight. That freedom is a competitive edge.\u003c\/p\u003e\n\n\u003cp\u003eThe financial position allows the company to fund shareholder returns and weather the sales dip - like the one experienced in the first nine months of 2025 - without needing to tap external credit markets or worry about restrictive debt covenants. As of June 30, 2025, cash and investments stood at \\$82.2 million. That’s a serious war chest for a company of this size.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Assessment: Debt-Free Status\u003c\/h3\u003e\n\u003cp\u003eHere’s how this specific resource scores across the VRIO framework. It’s a clear win for sustained advantage, honestly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The resource is definitely valuable. It allows for financial flexibility, helping the company navigate the 2025 sales environment, which saw revenues drop by about 7% for the nine months ending September 30, 2025. The strong liquidity means they can keep operating smoothly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Being completely debt-free while maintaining such high liquidity is relatively rare in the medical device sector. The current ratio at June 30, 2025, hit 41.9. That’s way up from the 25.6 ratio at the end of 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Copying the cash pile is tough without years of sustained profitability, but the organizational policy of avoiding debt is something a competitor could decide to copy starting tomorrow. The result is hard to copy; the policy is not.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company clearly exploits this strength. They are actively using this cash to support shareholders, which is a smart way to manage capital when organic growth is challenged. They don't just sit on it; they deploy it.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e This leads to a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e. It reflects a decade-plus of conservative financial management that competitors would need significant, disciplined execution over several years to match.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the financial health supporting this assessment:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eValue (as of 6\/30\/2025 or 9M 2025)\u003c\/td\u003e\n    \u003ctd\u003eSource Period\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash \u0026amp; Investments\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$82.2 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e41.9\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash Used for Share Repurchases\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$7,361 thousand\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e9M 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash Used for Dividends\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$3,006 thousand\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e9M 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe exploitation of this balance sheet is visible in their capital allocation strategy. They are prioritizing returning capital over taking on leverage, even when facing headwinds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003eFunded \\$7,361 thousand in share repurchases in 9M 2025.\u003c\/li\u003e\n  \u003cli\u003ePaid \\$3,006 thousand in dividends over 9M 2025.\u003c\/li\u003e\n  \u003cli\u003eMaintained zero long-term debt.\u003c\/li\u003e\n  \u003cli\u003eUsed cash to offset lower net income in 1H 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf onboarding new product lines takes longer than expected, churn risk rises for capital deployment, but the cash buffer minimizes the impact on operations.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUtah Medical Products, Inc. (UTMD) - VRIO Analysis: 2. Specialized Product Portfolio (Airway \u0026amp; Monitoring)\n\u003c\/h2\u003e\n\u003cp\u003eThe specialized product portfolio, encompassing airway management and monitoring devices, is assessed based on its contribution to UTMD's financial performance and market position.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides essential, non-discretionary single-use devices for acute and long-term care, ensuring consistent demand.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConsolidated total revenues for the year ended December 31, 2023, were $73.71 Million.\u003c\/li\u003e\n\u003cli\u003eThe company achieved a record Earnings Per Share (EPS) of $4.57 in 2023.\u003c\/li\u003e\n\u003cli\u003eGross Profit Margin (GPM) for 1H 2023 was 61.4%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific, established product line in niche areas like airway management is not easily replicated by general device makers.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUTMD's focus areas include devices for women and babies' healthcare, blood pressure monitoring, blood collection, electrosurgery, gynecology, neonatal critical care, perinatology, and urology.\u003c\/li\u003e\n\u003cli\u003eThe company is a distributor for the Filshie Clip System in the U.S..\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High initial R\u0026amp;D and regulatory hurdles make direct imitation slow and costly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch \u0026amp; Development (R\u0026amp;D) expenses in 1Q 2022 were $123 thousand.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses represented 1.0% of sales in 1Q 2022.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The leadership team guides product pipeline advancement and maintains compliance, supporting this portfolio.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEnding Cash and Investments on June 30, 2024, totaled $89.2 million.\u003c\/li\u003e\n\u003cli\u003eThe company paid $2.2 million in cash dividends to stockholders during 1H 2024.\u003c\/li\u003e\n\u003cli\u003eThe company repurchased $9.4 million of its common stock during 1H 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as patents expire and new technologies emerge, but currently strong due to established clinical use.\u003c\/p\u003e\n\u003cp\u003eThe financial impact of specific product lines within the portfolio shows dependency and potential vulnerability:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003e2022 Amount\u003c\/td\u003e\n\u003ctd\u003e2023 Amount\u003c\/td\u003e\n\u003ctd\u003e1H 2024 vs 1H 2023 Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales to PendoTECH (Monitoring Proxy)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown $2,788 thousand (57.5%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Consolidated Sales (USD)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eApprox. $73.71 Million\u003c\/td\u003e\n\u003ctd\u003eDown $3,646 thousand (14.4%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin (GPM)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e1H 2024: 59.9% vs 1H 2023: 61.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eUtah Medical Products, Inc. (UTMD) - VRIO Analysis: 3. Clean-Room Manufacturing \u0026amp; Regulatory Compliance\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eEnsures all devices meet the stringent regulatory standards required for sterile, single-use medical products, which is non-negotiable for hospital adoption.\u003c\/p\u003e\n\u003cp\u003eThe commitment to these standards is reflected in the investment in fixed assets, with net $10,552 thousand in total Property, Plant and Equipment (PP\u0026amp;E), including manufacturing molds, tooling, and equipment, reported at the end of 2023.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eWhile many firms have clean rooms, UTMD’s long-standing reputation for quality in this specific area is a known asset.\u003c\/p\u003e\n\u003cp\u003eUTMD's manufacturing infrastructure includes facilities in the U.S. and Ireland totaling a combined 220,000 square feet on 15 acres of land as of 2021.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eVery high imitability barrier due to the massive capital investment and the time needed to build a proven track record with the FDA and other bodies.\u003c\/p\u003e\n\u003cp\u003eThe initial capital outlay for a Good Manufacturing Practice (GMP)-compliant plant typically starts at $5 million, potentially exceeding $50 million for larger, highly automated facilities. Bringing a low-to-moderate-risk medical device to market costs an average of $31 million, with $24 million specifically dedicated to FDA-related stages.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eManufacturing processes in the U.S. and Ireland are structured around these high standards, though tariffs on imports from Ireland were a 2025 headwind.\u003c\/p\u003e\n\u003cp\u003eThe impact of international operations and associated costs is evident in recent margin compression:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe consolidated 1H 2025 Gross Profit Margin (GPM) was 56.6%, compared to 59.9% in 1H 2024.\u003c\/li\u003e\n\u003cli\u003eThe consolidated 2Q 2025 GP margin was 56.2% compared to 60.1% in 2Q 2024.\u003c\/li\u003e\n\u003cli\u003eThe lower margins in 1H 2025 were primarily attributed to Ireland operations due to factors including lower sales absorbing less fixed manufacturing overhead costs.\u003c\/li\u003e\n\u003cli\u003eMedical devices have been subject to a 10% baseline tariff since April 2025, with a 15% tariff imposed on EU pharmaceutical imports in August 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRecent financial performance metrics provide context for the operational environment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eLatest Reported Value\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing 12-Month Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.6M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 30-Sep-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommon Shares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,281,816\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 25, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Consolidated 2Q WW Sales (USD terms)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9,953 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2Q 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLitigation Costs (G\u0026amp;A)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$751 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e1Q 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained, as regulatory trust is built over decades, not quarters.\u003c\/p\u003e\n\u003cp\u003eThe Filshie Clip System, acquired in 2011, represented 26% of UTMD's total U.S. Dollar denominated sales in 2024. Litigation costs to defend the reputation of this device increased almost $1 million in 2023 compared to 2022.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUtah Medical Products, Inc. (UTMD) - VRIO Analysis: 4. Established Global Distribution Network\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides access to diverse revenue streams across North America, Europe, Asia, and Latin America, mitigating risk from single-market slowdowns.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A mature, multi-continent network of distributors and direct sales is hard-won.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; requires years of relationship building and navigating international logistics and compliance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company actively serves these markets, though 2025 saw trade uncertainty affect some outside-U.S. distributors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as these relationships are sticky and difficult for new entrants to displace.\u003c\/p\u003e\n\n\u003cp\u003eThe global reach is evidenced by established relationships with more than 300 international distributors and representation in all major developed countries and many underdeveloped countries. In 2022, 39% of consolidated total sales were to international customers.\u003c\/p\u003e\n\n\u003cp\u003eThe company maintains direct sales channels in specific international markets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIreland\u003c\/li\u003e\n\u003cli\u003eUnited Kingdom (UK)\u003c\/li\u003e\n\u003cli\u003eCanada\u003c\/li\u003e\n\u003cli\u003eAustralia\u003c\/li\u003e\n\u003cli\u003eNew Zealand\u003c\/li\u003e\n\u003cli\u003eFrance\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRecent financial data highlights the scale and activity within this network:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Percentage\u003c\/th\u003e\n\u003cth\u003ePeriod\/Year\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Sales Percentage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e39%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003eConsolidated Total Sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOUS Sales to Distributors\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5,136\u003c\/strong\u003e thousand\u003c\/td\u003e\n\u003ctd\u003e1H 2025\u003c\/td\u003e\n\u003ctd\u003eSales to distributors in other countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Consolidated Sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$19,663\u003c\/strong\u003e thousand\u003c\/td\u003e\n\u003ctd\u003e1H 2025\u003c\/td\u003e\n\u003ctd\u003eWorldwide (WW) sales in USD terms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK Subsidiary Trade Sales to Distributors\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3,347\u003c\/strong\u003e thousand\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eTo domestic UK and certain international distributor customers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustralia\/New Zealand End-User Sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1,050\u003c\/strong\u003e thousand\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eUSD-denominated sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanada End-User Sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1,102\u003c\/strong\u003e thousand\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eUSD-denominated sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eForeign currency fluctuations continue to impact reported international sales figures. For instance, in 1Q 2024, sales outside the U.S. (OUS) were 3% lower in USD terms compared to 1Q 2023, with 31% of consolidated USD sales being invoiced in foreign currencies during 1Q 2024. The UK subsidiary's trade sales to domestic UK and certain international distributor customers in 2023 were $3,347 thousand, representing a 20% increase over 2022's $2,781 thousand.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUtah Medical Products, Inc. (UTMD) - VRIO Analysis: 5. Direct Domestic Sales Channel Dominance\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Direct sales to hospitals and surgical centers represent \u003cstrong\u003e69%\u003c\/strong\u003e of total domestic sales and grew \u003cstrong\u003e+9.8%\u003c\/strong\u003e in the first nine months of \u003cstrong\u003e2025\u003c\/strong\u003e, showing strong end-user pull. Direct domestic Filshie device sales, representing \u003cstrong\u003e19%\u003c\/strong\u003e of total domestic sales, grew \u003cstrong\u003e+7.5%\u003c\/strong\u003e in 9M 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A high percentage of direct sales in a specialized field suggests strong brand loyalty and effective sales force management. The direct other device sales growth of \u003cstrong\u003e+9.8%\u003c\/strong\u003e in 9M 2025 contrasts with the overall domestic sales decline of \u003cstrong\u003e2.3%\u003c\/strong\u003e for the same period.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; building a specialized, knowledgeable direct sales force takes significant time and training.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company’s structure supports this channel, which outperformed the overall domestic sales decline in 9M 2025. The company’s total domestic sales were \u003cstrong\u003e$17,308\u003c\/strong\u003e thousand in 9M 2025, down from \u003cstrong\u003e$17,709\u003c\/strong\u003e thousand in 9M 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as competitors can hire away top talent or invest heavily in their own direct channels.\u003c\/p\u003e\n\u003cp\u003eDomestic Sales Component Breakdown (9M 2025 vs 9M 2024):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic Sales Component\u003c\/td\u003e\n\u003ctd\u003ePercentage of Total Domestic Sales (9M 2025)\u003c\/td\u003e\n\u003ctd\u003e9M 2025 vs 9M 2024 Change\u003c\/td\u003e\n\u003ctd\u003e9M 2025 Growth Amount (in thousands)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Other Device Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+9.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+$1,072\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic OEM Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(46.3%)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$1,706\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Domestic Filshie Device Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+7.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+$233\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSupporting Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal consolidated 9M 2025 UTMD WW consolidated sales were \u003cstrong\u003e7.2%\u003c\/strong\u003e lower than in 9M 2024.\u003c\/li\u003e\n\u003cli\u003eU.S. domestic sales in 9M 2025 were \u003cstrong\u003e2.3%\u003c\/strong\u003e lower than in 9M 2024.\u003c\/li\u003e\n\u003cli\u003eThe PendoTECH portion of domestic OEM sales were \u003cstrong\u003e(84.6%)\u003c\/strong\u003e lower in 9M 2025.\u003c\/li\u003e\n\u003cli\u003eManufacturing costs in 9M 2025 included U.S. tariffs of \u003cstrong\u003e$94\u003c\/strong\u003e thousand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUtah Medical Products, Inc. (UTMD) - VRIO Analysis: 6. Intangible Assets Base (IP \u0026amp; Goodwill)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Represents the recorded value of intellectual property and brand equity, underpinning future product development and market perception. Net Intangible Assets were \u003cstrong\u003e13.4%\u003c\/strong\u003e of total assets at June 30, 2025. Total consolidated assets at June 30, 2025 were \u003cstrong\u003e$120,802\u003c\/strong\u003e thousand.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntangible Asset Component (Millions USD)\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGoodwill\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.58\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e13.35\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther Intangible Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.87\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2.87\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The level of recorded intangibles is specific to UTMD’s history of acquisitions and internal development. At June 30, 2025, despite a weaker USD, GBP-valued intangible assets increased \u003cstrong\u003e8.6%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The value is hard to imitate, but the components (patents) can be copied once they expire. Research and Development expenses in 1Q 2025 were \u003cstrong\u003e$155\u003c\/strong\u003e thousand (\u003cstrong\u003e1.6%\u003c\/strong\u003e of sales), a decrease from 1Q 2024 R\u0026amp;D expenses of \u003cstrong\u003e$266\u003c\/strong\u003e thousand (\u003cstrong\u003e2.3%\u003c\/strong\u003e of sales).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Management tracks this, noting a slight decrease in the Net Intangible Assets percentage from \u003cstrong\u003e13.5%\u003c\/strong\u003e on June 30, 2024, to \u003cstrong\u003e13.4%\u003c\/strong\u003e on June 30, 2025, despite a weaker USD boosting GBP-valued assets by \u003cstrong\u003e8.6%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the company continues to invest in R\u0026amp;D to replenish the IP pipeline.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Intangible Assets as a percentage of total consolidated assets were \u003cstrong\u003e12.7%\u003c\/strong\u003e at September 30, 2025, down from \u003cstrong\u003e13.4%\u003c\/strong\u003e at December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eThe company has no debt.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUtah Medical Products, Inc. (UTMD) - VRIO Analysis: 7. Experienced, Specialized Leadership Team\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nProvides stability and deep domain knowledge in medical device engineering, regulatory affairs, and quality assurance, crucial for navigating complex healthcare environments.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eChairman, CEO, President, and Secretary since December 1992: Kevin L. Cornwell.\u003c\/li\u003e\n\u003cli\u003eChairman of the Board since 1996: Kevin L. Cornwell.\u003c\/li\u003e\n\u003cli\u003ePrincipal Financial Officer since April 2018: Brian L. Koopman.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003e\nDeep, relevant experience across all critical functions is not common in smaller public companies.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeadership Role\u003c\/td\u003e\n\u003ctd\u003eTenure\/Start Year\u003c\/td\u003e\n\u003ctd\u003eRelevant Experience Detail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChairman\/CEO\/President\u003c\/td\u003e\n\u003ctd\u003eSince 1992 \/ 1996\u003c\/td\u003e\n\u003ctd\u003eOver 42-year time span in senior operating management positions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead Independent Director\u003c\/td\u003e\n\u003ctd\u003eSince 1996\u003c\/td\u003e\n\u003ctd\u003eFifteen years as General Manager of Petersen Precision Engineering Company\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoard Average Tenure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23.4 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003e\nHigh; you can’t buy experience or the institutional knowledge built over decades.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eExecutive\u003c\/td\u003e\n\u003ctd\u003eTenure Length (Approximate)\u003c\/td\u003e\n\u003ctd\u003eSpecific Experience Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKevin L. Cornwell\u003c\/td\u003e\n\u003ctd\u003eOver 33 years in top executive roles\u003c\/td\u003e\n\u003ctd\u003eB.S. Chemical Engineering (Stanford), M.S. Management Science (Stanford), MBA (Stanford GSB)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Board Member (Legal)\u003c\/td\u003e\n\u003ctd\u003eOver 20 years as outside legal counsel prior to 2025\u003c\/td\u003e\n\u003ctd\u003eJ.D. from University of Utah College of Law (1997)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Board Member (Sales)\u003c\/td\u003e\n\u003ctd\u003e12 years in direct sales roles (2004 to 2016)\u003c\/td\u003e\n\u003ctd\u003eManager of Global Direct End User Sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003e\nThis team guides the company's strategy, which has kept financial results consistent with projections despite external headwinds.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eQ2 and 1H 2025 financial results were consistent with the projections provided at the beginning of the year.\u003c\/li\u003e\n\u003cli\u003e1Q 2025 financial results were consistent with its previously announced projections for calendar year 2025.\u003c\/li\u003e\n\u003cli\u003e1Q 2023 financial results were consistent with achieving its goals previously announced for calendar year 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003e\nSustained, as leadership tenure creates a high barrier to entry for competitors trying to match strategic execution.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003eAmount\/Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecord Earnings Per Share (EPS)\u003c\/td\u003e\n\u003ctd\u003eYear 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.57\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.048 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Investments (No Debt)\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$82.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly Dividend\u003c\/td\u003e\n\u003ctd\u003eDeclared Nov 2025\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.31\u003c\/strong\u003e per share (a 1.6% increase)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eUtah Medical Products, Inc. (UTMD) - VRIO Analysis: 8. Established Shareholder Return Policy\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Signals financial maturity and commitment to returning capital, which supports the stock price and attracts a certain class of long-term investor. The quarterly dividend was recently increased to \u003cstrong\u003e\\$0.31\u003c\/strong\u003e per share. The annual dividend is \u003cstrong\u003e\\$1.22\u003c\/strong\u003e per share, representing a current dividend yield between \u003cstrong\u003e2.09%\u003c\/strong\u003e and \u003cstrong\u003e2.20%\u003c\/strong\u003e. UTMD has maintained dividend payments for \u003cstrong\u003e22 consecutive years\u003c\/strong\u003e. The company currently pays out \u003cstrong\u003e34.46%\u003c\/strong\u003e of its earnings and \u003cstrong\u003e24.96%\u003c\/strong\u003e of its cash flow as dividends.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDividend Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMost Recent Quarterly Dividend\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\\$0.31\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003ctd\u003eMost recent announced increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Dividend\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\\$1.22\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003ctd\u003eTrailing Twelve Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDividend Payout Ratio (Earnings)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e34.46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTrailing Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDividend Payout Ratio (Cash Flow)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24.96%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTrailing Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsecutive Years of Dividend Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMost recent data point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: While many firms pay dividends, a consistent policy supported by a debt-free balance sheet is notable. The balance sheet reflects a Total Debt of \u003cstrong\u003e\\$0.0\u003c\/strong\u003e. Total shareholder equity was reported at \u003cstrong\u003e\\$118.3M\u003c\/strong\u003e, with short-term assets of \u003cstrong\u003e\\$96.5M\u003c\/strong\u003e exceeding short-term liabilities of \u003cstrong\u003e\\$3.0M\u003c\/strong\u003e (as of a recent reporting period).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low; competitors can choose to return capital, but matching UTMD’s consistency requires similar financial discipline. The average annual dividend increase over the past 5 years was \u003cstrong\u003e1.74%\u003c\/strong\u003e. A recent quarterly dividend increase was reported as \u003cstrong\u003e1.7%\u003c\/strong\u003e over the prior year's same quarter dividend of \u003cstrong\u003e\\$0.305\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: The finance function actively executes this through dividends and share repurchases, showing clear intent. The company utilized cash for shareholder returns in recent years:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash used for share repurchases in \u003cstrong\u003e2022\u003c\/strong\u003e: \u003cstrong\u003e\\$2,495\u003c\/strong\u003e (in millions of dollars).\u003c\/li\u003e\n\u003cli\u003eCash used for share repurchases in \u003cstrong\u003e2020\u003c\/strong\u003e: \u003cstrong\u003e\\$6,976\u003c\/strong\u003e (in thousands of dollars).\u003c\/li\u003e\n\u003cli\u003eCash used for stockholder cash dividends in \u003cstrong\u003e2021\u003c\/strong\u003e: \u003cstrong\u003e\\$11,465\u003c\/strong\u003e (in thousands of dollars).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; a change in board strategy could eliminate this advantage quickly. The current Return on Equity (ROE) is reported at \u003cstrong\u003e10%\u003c\/strong\u003e, with a Price-to-Earnings (P\/E) ratio of \u003cstrong\u003e16.82\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUtah Medical Products, Inc. (UTMD) - VRIO Analysis: 9. Operational Diversification (US \u0026amp; Ireland)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Having manufacturing in both the U.S. and Ireland offers some redundancy and allows for different cost\/tariff structures, though 2025 showed tariffs on Irish imports were a factor. U.S. tariffs on imported components, mostly from UTMD Ireland, were \\$78 in 3Q 2025 compared to zero in 3Q 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Dual-country manufacturing for a company of this size is not standard; it shows a global operational mindset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; setting up a second, fully compliant facility takes significant time and capital.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization manages the complexity, though the lower absorption of fixed overhead in Ireland due to sales issues was a 2025 margin drag. An unexpected loss of \\$581 in revenues in 3Q 2025 reduced Ireland's gross profit margin by lower absorption of fixed manufacturing overhead expense.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the benefit is currently offset by the complexity of managing tariffs and foreign exchange impacts. The U.S. government recently set a 15% tariff on medical device imports from Ireland, which acts as a 'top-line' excise tax on intercompany sales to the U.S. from UTMD's Ireland subsidiary.\u003c\/p\u003e\n\u003cp\u003eThe operational structure supports a strong balance sheet, with a Current Ratio of 2.96 as of September 30, 2024.\u003c\/p\u003e\n\u003cp\u003eDraft 13-Week Cash Flow View Incorporating Q3 Cash Balance (Amounts in Thousands USD, Illustrative)\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eWeek 1\u003c\/th\u003e\n\u003cth\u003eWeek 2\u003c\/th\u003e\n\u003cth\u003eWeek 3\u003c\/th\u003e\n\u003cth\u003e...\u003c\/th\u003e\n\u003cth\u003eWeek 11\u003c\/th\u003e\n\u003cth\u003eWeek 12\u003c\/th\u003e\n\u003cth\u003eWeek 13\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$82,200\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\\$81,550\u003c\/td\u003e\n\u003ctd\u003e\\$80,900\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e\\$78,400\u003c\/td\u003e\n\u003ctd\u003e\\$77,750\u003c\/td\u003e\n\u003ctd\u003e\\$77,100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Inflows (Collections\/Other)\u003c\/td\u003e\n\u003ctd\u003e\\$4,500\u003c\/td\u003e\n\u003ctd\u003e\\$4,200\u003c\/td\u003e\n\u003ctd\u003e\\$4,800\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e\\$4,100\u003c\/td\u003e\n\u003ctd\u003e\\$4,500\u003c\/td\u003e\n\u003ctd\u003e\\$4,300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Outflows (Operating\/CapEx)\u003c\/td\u003e\n\u003ctd\u003e(\\$5,150)\u003c\/td\u003e\n\u003ctd\u003e(\\$5,850)\u003c\/td\u003e\n\u003ctd\u003e(\\$5,200)\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e(\\$5,500)\u003c\/td\u003e\n\u003ctd\u003e(\\$5,800)\u003c\/td\u003e\n\u003ctd\u003e(\\$5,400)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Flow\u003c\/td\u003e\n\u003ctd\u003e(\\$650)\u003c\/td\u003e\n\u003ctd\u003e(\\$1,650)\u003c\/td\u003e\n\u003ctd\u003e(\\$400)\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e(\\$1,400)\u003c\/td\u003e\n\u003ctd\u003e(\\$1,300)\u003c\/td\u003e\n\u003ctd\u003e(\\$1,100)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$81,550\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$80,900\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$80,500\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$78,400\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$77,750\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$77,100\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey Operational Financial Metrics Comparison (USD in Thousands)\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDomestic U.S. Sales 3Q 2023: \u003cstrong\u003e\\$7,265\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDomestic U.S. Sales 3Q 2024: \u003cstrong\u003e\\$5,687\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e3Q 2024 Net Income Margin: \u003cstrong\u003e35.6%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e3Q 2023 Net Income Margin: \u003cstrong\u003e31.5%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e9M 2025 Tariffs on Imported Components: \u003cstrong\u003e\\$94\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e3Q 2025 Revenue Loss from Distributor Cancellations: \u003cstrong\u003e\\$581\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516273713301,"sku":"utmd-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/utmd-vrio-analysis.png?v=1740227832","url":"https:\/\/dcf-model.com\/products\/utmd-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}